Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 567 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obesity Type 2 Diabetes Mellitus Clear all
Completed Not applicable Interventional

Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes

NCT00831194
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Personalized diet plan and PDA self reporting.
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Walking and Heating on Vascular Function in Diabetic Patients

NCT03203694
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Walking: Intervention arm in diabetics, Walking: No intervention in diabetics, Walking: Healthy cohort as reference controls, Lower body heating: Intervention arm in healthy subjects, Lower body heating: Intervention arm in diabetics, Lower body heating: Healthy cohort as reference controls
Behavioral · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes

NCT03193229
View directory record Official record
Conditions
Pre Diabetes, Obesity
Interventions
MapTrek, Fitbit
Behavioral · Device
Lead sponsor
Philip Polgreen
Other
Eligibility
21 Years to 80 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Coralville, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 15, 2026, 2:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

NCT07232719
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Riverside, California • Atlantis, Florida • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT06305351
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus (T2DM)
Interventions
K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Diabetes Prevention and Control in the Workplace: A Pilot Study

NCT00739336
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Diabetes Prevention and Control
Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Sleep and Media Use Intervention to Improve Adolescents' Weight and Risk of Type 2 Diabetes

NCT02451436
View directory record Official record
Conditions
Sleep
Interventions
Sleep and Media Use Intervention, Study Skills Control Group
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 15, 2026, 2:16 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 15, 2026, 2:16 AM EDT
Not yet recruiting Not applicable Interventional

Ability of Almonds to Improve Nutrition During GLP-1 Treatment

NCT07796204
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Almond Diet
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01807377
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-05175157, Midazolam, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional

A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients

NCT00779363
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
rechargeable TANTALUS II
Device
Lead sponsor
MetaCure (USA), Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindfulness-Based Intervention for Depression and Insulin Resistance in Adolescents

NCT04992299
View directory record Official record
Conditions
Type 2 Diabetes, Depression, Insulin Resistance, Obesity, Adolescent Development
Interventions
Mindfulness-Based Intervention, Cognitive-Behavioral Therapy, Health Education
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
12 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Terminated Phase 4 Interventional

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598
View directory record Official record
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 15, 2026, 2:16 AM EDT
Recruiting Not applicable Interventional

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821
View directory record Official record
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Recruiting Not applicable Interventional

Plant-Based Online Weight Loss Through Education and Resources Program and Study

NCT07095543
View directory record Official record
Conditions
Type 2 Diabetes, Overweight and Obese Adults
Interventions
Low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

NCT05958368
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin, Fructosamine, C-Reactive Protein, Glucose, Overweight and Obesity
Interventions
Avocado, Other Fruit(s)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Worksite Nutrition Study

NCT00481897
View directory record Official record
Conditions
Overweight, Type 2 Diabetes
Interventions
low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Weight Loss With SGLT2 Inhibition

NCT02360774
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional

Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes

NCT00200018
View directory record Official record
Conditions
Severe to Morbid Obesity and Type 2 Diabetes
Interventions
Enterra Therapy System (H9900014)
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
La Jolla, California • Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Beta Cell Restoration Through Fat Mitigation

NCT01763346
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes, Obesity
Interventions
Metformin, gastric banding
Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
22 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 15, 2026, 2:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).

NCT00361946
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 15, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

NCT00659711
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Januvia (Sitagliptin) 100 mg, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 15, 2026, 2:16 AM EDT